Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. more
Time Frame | QURE | Sector | S&P500 |
---|---|---|---|
1-Week Return | 7.58% | -3.39% | 0.2% |
1-Month Return | 166.34% | -1.92% | 2.72% |
3-Month Return | 192.88% | -10.54% | 7.31% |
6-Month Return | 250.96% | -4.47% | 10.44% |
1-Year Return | 106.27% | 4.06% | 27.53% |
3-Year Return | -22.47% | 0.94% | 30.88% |
5-Year Return | -77.13% | 36.67% | 89.21% |
10-Year Return | 9.01% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 7.28M | 37.51M | 524.00M | 106.48M | 15.84M | [{"date":"2019-12-31","value":1.39,"profit":true},{"date":"2020-12-31","value":7.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":20.32,"profit":true},{"date":"2023-12-31","value":3.02,"profit":true}] |
Cost of Revenue | 94.74M | 122.40M | 24.98M | 3.34M | 13.63M | [{"date":"2019-12-31","value":77.4,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":20.41,"profit":true},{"date":"2022-12-31","value":2.73,"profit":true},{"date":"2023-12-31","value":11.13,"profit":true}] |
Gross Profit | (87.46M) | (84.89M) | 499.03M | 103.14M | 2.21M | [{"date":"2019-12-31","value":-17.53,"profit":false},{"date":"2020-12-31","value":-17.01,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":20.67,"profit":true},{"date":"2023-12-31","value":0.44,"profit":true}] |
Gross Margin | (1201.15%) | (226.28%) | 95.23% | 96.86% | 13.98% | [{"date":"2019-12-31","value":-1240.09,"profit":false},{"date":"2020-12-31","value":-233.61,"profit":false},{"date":"2021-12-31","value":98.32,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":14.43,"profit":true}] |
Operating Expenses | 128.42M | 162.94M | 188.41M | 246.30M | 285.09M | [{"date":"2019-12-31","value":45.05,"profit":true},{"date":"2020-12-31","value":57.15,"profit":true},{"date":"2021-12-31","value":66.09,"profit":true},{"date":"2022-12-31","value":86.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (121.14M) | (125.43M) | 310.62M | (143.16M) | (282.87M) | [{"date":"2019-12-31","value":-39,"profit":false},{"date":"2020-12-31","value":-40.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-46.09,"profit":false},{"date":"2023-12-31","value":-91.07,"profit":false}] |
Total Non-Operating Income/Expense | (3.32M) | (18.90M) | 14.88M | 3.81M | (40.07M) | [{"date":"2019-12-31","value":-22.34,"profit":false},{"date":"2020-12-31","value":-127.08,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":25.58,"profit":true},{"date":"2023-12-31","value":-269.37,"profit":false}] |
Pre-Tax Income | (124.20M) | (141.44M) | 332.81M | (128.26M) | (306.56M) | [{"date":"2019-12-31","value":-37.32,"profit":false},{"date":"2020-12-31","value":-42.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.54,"profit":false},{"date":"2023-12-31","value":-92.11,"profit":false}] |
Income Taxes | 3.81M | (16.42M) | 3.22M | (1.47M) | 1.92M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-430.94,"profit":false},{"date":"2021-12-31","value":84.44,"profit":true},{"date":"2022-12-31","value":-38.58,"profit":false},{"date":"2023-12-31","value":50.42,"profit":true}] |
Income After Taxes | (128.01M) | (125.02M) | 329.59M | (126.79M) | (308.48M) | [{"date":"2019-12-31","value":-38.84,"profit":false},{"date":"2020-12-31","value":-37.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.47,"profit":false},{"date":"2023-12-31","value":-93.59,"profit":false}] |
Income From Continuous Operations | (124.20M) | (125.02M) | 329.59M | (126.79M) | (228.47M) | [{"date":"2019-12-31","value":-37.68,"profit":false},{"date":"2020-12-31","value":-37.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.47,"profit":false},{"date":"2023-12-31","value":-69.32,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (128.01M) | (125.02M) | 329.59M | (126.79M) | (308.48M) | [{"date":"2019-12-31","value":-38.84,"profit":false},{"date":"2020-12-31","value":-37.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.47,"profit":false},{"date":"2023-12-31","value":-93.59,"profit":false}] |
EPS (Diluted) | (3.11) | (2.81) | 6.98 | (2.71) | (6.48) | [{"date":"2019-12-31","value":-44.56,"profit":false},{"date":"2020-12-31","value":-40.26,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.83,"profit":false},{"date":"2023-12-31","value":-92.84,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
QURE | |
---|---|
Cash Ratio | 6.11 |
Current Ratio | 6.51 |
Quick Ratio | 6.51 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
QURE | |
---|---|
ROA (LTM) | -16.62% |
ROE (LTM) | -147.57% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
QURE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.91 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.09 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
QURE | |
---|---|
Trailing PE | NM |
Forward PE | 27.93 |
P/S (TTM) | 29.67 |
P/B | 13.45 |
Price/FCF | NM |
EV/R | 13.40 |
EV/Ebitda | 0.99 |
PEG | NM |
Uniqure NV (QURE) share price today is $17.082
Yes, Indians can buy shares of Uniqure NV (QURE) on Vested. To buy Uniqure NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in QURE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Uniqure NV (QURE) via the Vested app. You can start investing in Uniqure NV (QURE) with a minimum investment of $1.
You can invest in shares of Uniqure NV (QURE) via Vested in three simple steps:
The 52-week high price of Uniqure NV (QURE) is $17.71. The 52-week low price of Uniqure NV (QURE) is $3.73.
The price-to-earnings (P/E) ratio of Uniqure NV (QURE) is
The price-to-book (P/B) ratio of Uniqure NV (QURE) is 13.45
The dividend yield of Uniqure NV (QURE) is 0.00%
The market capitalization of Uniqure NV (QURE) is $848.13M
The stock symbol (or ticker) of Uniqure NV is QURE